Bank of New York Mellon’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-133,230
| Closed | -$304K | – | 4180 |
|
|
2024
Q2 | $304K | Buy |
+133,230
| New | +$509K | ﹤0.01% | 3811 |
|
|
2024
Q1 | – | Sell |
-17,607
| Closed | -$53.7K | – | 4342 |
|
|
2023
Q4 | $53.7K | Hold |
17,607
| – | – | ﹤0.01% | 4155 |
|
|
2023
Q3 | $25.4K | Hold |
17,607
| – | – | ﹤0.01% | 4230 |
|
|
2023
Q2 | $43.8K | Sell |
17,607
-1,687
| -9% | -$4.61K | ﹤0.01% | 4196 |
|
|
2023
Q1 | $51.7K | Hold |
19,294
| – | – | ﹤0.01% | 4193 |
|
|
2022
Q4 | $105K | Sell |
19,294
-203
| -1% | -$1.7K | ﹤0.01% | 4106 |
|
|
2022
Q3 | $243K | Buy |
19,497
+3,872
| +25% | +$44.2K | ﹤0.01% | 3933 |
|
|
2022
Q2 | $77K | Sell |
15,625
-114,645
| -88% | -$635K | ﹤0.01% | 4285 |
|
|
2022
Q1 | $990K | Buy |
130,270
+301
| +0.2% | +$2.85K | ﹤0.01% | 3328 |
|
|
2021
Q4 | $1.33M | Buy |
129,969
+4,719
| +4% | +$60.1K | ﹤0.01% | 3223 |
|
|
2021
Q3 | $1.68M | Buy |
125,250
+10,424
| +9% | +$170K | ﹤0.01% | 3095 |
|
|
2021
Q2 | $2.52M | Sell |
114,826
-15,941
| -12% | -$354K | ﹤0.01% | 2849 |
|
|
2021
Q1 | $3.15M | Sell |
130,767
-768
| -0.6% | -$17.8K | ﹤0.01% | 2665 |
|
|
2020
Q4 | $2.37M | Sell |
131,535
-8,680
| -6% | -$130K | ﹤0.01% | 2746 |
|
|
2020
Q3 | $1.62M | Sell |
140,215
-806
| -0.6% | -$13.3K | ﹤0.01% | 2793 |
|
|
2020
Q2 | $3.42M | Buy |
141,021
+7,295
| +5% | +$121K | ﹤0.01% | 2401 |
|
|
2020
Q1 | $1.47M | Sell |
133,726
-575
| -0.4% | -$10.7K | ﹤0.01% | 2715 |
|
|
2019
Q4 | $3.55M | Buy |
134,301
+2,024
| +2% | +$47.3K | ﹤0.01% | 2511 |
|
|
2019
Q3 | $3.01M | Sell |
132,277
-2,867
| -2% | -$90.4K | ﹤0.01% | 2529 |
|
|
2019
Q2 | $4.14M | Sell |
135,144
-979,181
| -88% | -$20.6M | ﹤0.01% | 2421 |
|
|
2019
Q1 | $18.5M | Buy |
1,114,325
+27,415
| +3% | +$520K | 0.01% | 1592 |
|
|
2018
Q4 | $20.8M | Sell |
1,086,910
-178,972
| -14% | -$6.7M | 0.01% | 1447 |
|
|
2018
Q3 | $66.2M | Buy |
1,265,882
+2,891
| +0.2% | +$158K | 0.02% | 837 |
|
|
2018
Q2 | $54.9M | Buy |
1,262,991
+1,183,940
| +1,498% | +$50.7M | 0.01% | 941 |
|
|
2018
Q1 | $2.93M | Buy |
79,051
+49,710
| +169% | +$1.33M | ﹤0.01% | 2617 |
|
|
2017
Q4 | $582K | Buy |
29,341
+6,483
| +28% | +$139K | ﹤0.01% | 3551 |
|
|
2017
Q3 | $568K | Buy |
+22,858
| New | +$422K | ﹤0.01% | 3526 |
|
Bank of New York Mellon's GTHX Position: Q3 2024 in Review
Bank of New York Mellon sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 133,230 shares — an estimated $304K sold.
Bank of New York Mellon first reported a position in GTHX in Q3 2017 and held it in 27 quarters. The position peaked at $66.2M in Q3 2018. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Bank of New York Mellon reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Bank of New York Mellon sold 133,230 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $304K.
- Bank of New York Mellon first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2017 and held it in 27 quarters.
- Bank of New York Mellon's G1 Therapeutics, Inc. Common Stock position peaked at $66.2M in Q3 2018.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Bank of New York Mellon's 13F filing for Q3 2024, filed 12 Nov 2024.